Béatrice Llirbat

Nessuna posizione attualmente

59 anni

Health Technology

Consumer Services

Finance

Profilo

Dr. Béatrice Llirbat is on the Board of Directors at Kadrige SA. Dr. Llirbat was previously employed as Partner by Amundi Private Equity Funds SA, Partner by Société Générale Asset Mgmt Alternative Invt (Private Equity), Member-Supervisory Board by Génomic Vision SA, Member-Supervisory Board by Genticel SA, and Member-Supervisory Board by Trophos SA. He also served on the board at Intrasense SA, Adocia SA and Arterial Remodelling Technologies SA. He received his doctorate degree from the University of Paris V and a doctorate degree from Université Pierre et Marie Curie.

Precedenti posizioni note di Béatrice Llirbat

Società	Posizione	Fine
Amundi Private Equity Funds SA Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity invests in companies located in France. The firm targets companies operating in the fields of technology, demographics, and environment. It provides financing for growth and buyout stage capital requirements. It also acquires minority or majority interest and it takes board seat.	Investitore di Private Equity	31/12/2012
Société Générale Asset Mgmt Alternative Invt (Private Equity) Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia.	Investitore di Private Equity	16/02/2010
Arterial Remodelling Technologies SA Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Develops bioresorbable peripheral and coronary polymer stents	Direttore/Membro del Consiglio	-
Kadrige SA Kadrige SA Data Processing ServicesTechnology Services Provides technology solutions for promotion, information, training and remote management services	Direttore/Membro del Consiglio	-
GENOMIC VISION	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Béatrice Llirbat

Formazione di Béatrice Llirbat

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Béatrice Llirbat

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	11
Trophos SA Trophos SA Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention of neuronal loss for neurodegenerative diseases	Health Technology
Université Pierre et Marie Curie Université Pierre et Marie Curie Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Société Générale Asset Mgmt Alternative Invt (Private Equity) Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia.	Finance
Arterial Remodelling Technologies SA Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Develops bioresorbable peripheral and coronary polymer stents	Health Technology
Kadrige SA Kadrige SA Data Processing ServicesTechnology Services Provides technology solutions for promotion, information, training and remote management services	Technology Services
Génomic Vision SA Génomic Vision SA Medical SpecialtiesHealth Technology Develops diagnostic tools using deoxyribonucleic acid analysis	Health Technology
Genticel SA Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus	Health Technology
Intrasense SA Intrasense SA Packaged SoftwareTechnology Services Develops and markets software solutions for viewing and analyzing of medical images	Technology Services
Adocia SA Adocia SA Pharmaceuticals: MajorHealth Technology Manufactures novel therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases	Health Technology
Amundi Private Equity Funds SA Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity invests in companies located in France. The firm targets companies operating in the fields of technology, demographics, and environment. It provides financing for growth and buyout stage capital requirements. It also acquires minority or majority interest and it takes board seat.	Finance
Université de Paris 5 René Descartes Université de Paris 5 René Descartes Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services